Superbug showdown: which drug combo wins?
NCT ID NCT07524920
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two different antibiotic combinations to see which works better at wiping out multi-drug resistant bacteria in adults. Sixty hospitalized patients will receive either Colistin plus Meropenem or Imipenem/cilastatin plus Tigecycline. Researchers will track lab results, symptoms, and side effects to find the safer, more effective option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- antibiotic combinations (Colistin + Meropenem vs Imipenem/cilastatin + Tigecycline)
- What this could lead to
- If one combination works better, it could offer a more effective way to treat hard-to-kill bacterial infections in hospitalized patients.
- What could go wrong
- This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. Both antibiotic combos can cause kidney or liver side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDR BACTERIA are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
El-Demerdash hospital
Cairo, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.